This is a demo store. No orders will be fulfilled.
USD
GBP
CNY
EUR
INR
JPY
MYR
ZAR
KRW
THB
Life Sciences
Frost & Sullivan's expertise in Life Sciences research and consulting includes work in diversified strategic and operational areas
The life sciences industry is undergoing rapid change, dynamic discoveries and pressures driving business decisions and corporate growth. Business models are being forced to evolve as healthcare continues to shift from a treatment focus to points of wellness, prediction, personalization, and prevention.
Recognizing the interdependence of the payer, provider and pharmaceutical value chains, companies are re-inventing strategies in multitude ways: increased outsourcing, co-development and patient engagement are the new norms.
The Frost & Sullivan Global Life Sciences Program helps you better understand stakeholder dynamics as the healthcare system transitions from acute care into integrated care. Our research and insights help you make informed strategic decisions around how best to navigate this complex market.
We can support needs from syndicated research to projects ranging from proprietary strategic engagements and market research, marketing solutions, and whitepapers, all leveraging the global reach of our firm to propel your business forward.
We believe a structured partnership that provides you transformational insights through online content as well as deeper interaction with our senior analyst team will help ensure greater relevancy of insights provided for your organization.
-
30 Nov 2021 | Global | Technology Research
Targeted Immunotherapy in Oncology
Developments in Biotechnology Platforms Leading to Increasing Immuno-oncology Applications
This research service investigates technologies that propel the development of new targeted immunotherapies, particularly those that deliver therapeutic DNA and proteins. The top 3 growth opportunities focus on enhanced gene delivery systems for greater precision, the support of such systems through novel biotech platforms, and the affordability of...
$4,950.00 -
24 Nov 2021 | Global | Technology Research
Technology Developments in Viral Vector Manufacturing for Cell and Gene Therapies
Need for Scalable, Reproducible, and Cost-Effective Manufacturing Processes Driving Growth Opportunities
The Frost & Sullivan research service discusses the cell and gene therapy (CGT) market and highlights some key roadblocks in viral vector manufacturing. While many CGT candidates exist in the pipeline, there is a huge capacity deficit that the industry is collaboratively trying to address. Scalability, costs, reproducibility, and overall process ef...
$4,950.00 -
22 Nov 2021 | Global | Technology Research
Technological Advances in RNA Stabilization & Delivery
LNP- and Bioconjugation-based Nonviral RNA Delivery Technologies to Gain Momentum in the Next 3 Years
RNA therapeutics is a rapidly expanding field of next-generation medicine. RNA therapy typically comprises 4 different classes of molecules: non-codingRNA (ncRNA), antisense oligonucleotide (ASO), messengerRNA (mRNA), and RNA aptamer. Small ncRNAs are like a double-edged sword; they can either up- or down-regulate specific genes. Contrarily, long...
$4,950.00 -
23 Jun 2021 | Global | Technology Research
Global RNA Therapeutics:Technology Growth Opportunities
Advances in RNA Modifications, Formulation, and Stabilization to Drive Growth of RNA Therapeutics
RNA therapeutics is a rapidly expanding area of next-generation biological drugs. RNA is a versatile molecule and naturally regulates gene expression, either by upregulation or downregulation. This function is employed to design novel RNA therapeutics. The fundamentals of RNA therapeutics consists of delivering functional RNA at a target; however, ...
$4,950.00 -
27 Dec 2018 | Global | Technology Research
Microbiome Technologies Fueling Human Health and Wellness
Emerging Microbiome Platforms Disrupting Pharmaceutical, Food & Beverages and the Consumer Care Industries
This research service encompasses microbiome technology trends and emerging innovations across: Disease Management This research segment explores the emerging role of microbiome-based therapeutics across a wide range of diseases, especially in the context of gastro-intestinal health, while providing strategic insights across the highly dynamic com...
$4,950.00 -
13 Nov 2018 | Global | Technology Research
Artificial Intelligence Revolutionizing the Pharmaceutical Industry
Optimal Synergy Between Leading-edge Computational Science and Therapeutics Development
The impressive advances in life sciences research and development (R&D) befallen in the past two-three years are playing a leading role in the transformation of the healthcare industry. A myriad of new developments in the fields of gene and cell therapies, empowered with nanotechnology advances, omics technologies and novel smart molecules approach...
$4,950.00 -
28 Sep 2018 | North America | Technology Research
Gene Editing and Gene Therapy Breakthroughs to Propel Mainstream Disease Treatments
A new wave of gene therapies is set to revolutionize treatments over the next decade for inherited diseases which are either untreatable or which do not have a satisfactory treatment outcome at present
The drug approvals of Yescarta (axicabtagene ciloleucel), Luxturna (Voretigene neparvovec) and Kymriah (Tisagenlecleucel) have turned a leaf in the pharmaceutical chapter of gene therapy development. Currently, genetic disorders do not have satisfactory treatment outcomes. This is in part due to the inability of small molecule drugs and enzyme repl...
$4,950.00 -
29 Jun 2018 | Global | Technology Research
Novel Therapies for Rare and Genetic Diseases
Unveiling One of the Most Promising Fields of Therapeutic Technology Synergy
Recent advancement in the development of novel platforms of smart targeting small molecules, gene therapy, stem cell therapy, gene modification, and gene rectification technologies pose new prospects for therapies and cures for rare and genetic diseases. More than 80% of rare diseases are genetic in origin, so that gene and cell therapies are being...
$4,950.00
